Envoy Medical Corporation and Anzu Special Acquisition Corp I Complete Business Combination
White Bear Lake, Minnesota and Tampa, Florida--(Newsfile Corp. - September 29, 2023) - Anzu Special Acquisition Corp I (NASDAQ: ANZU) (NASDAQ: ANZUU) (NASDAQ: ANZUW) ("Anzu"), a special purpose acquisition company, and Envoy Medical Corporation ("Envoy" or "Envoy Medical"), a hearing health company, announced today the completion of their previously announced business combination ("the Business Combination"), resulting in Envoy becoming a publicly listed company. The combined company will operate under the name "Envoy Medical, Inc." and its Class A common stock and warrants are expected to commence trading on October 2, 2023, on the Nasdaq stock exchange under the new ticker symbols "COCH" and "COCHW", respectively.
Envoy Medical Announces Shareholder Approval on Proposed Merger with Anzu Special Acquisition Corp I
White Bear Lake, Minnesota--(Newsfile Corp. - September 28, 2023) - Envoy Medical® Corporation ("Envoy"), a hearing health company, today announced that the proposed merger with Anzu Special Acquisition Corp I (NASDAQ: ANZU) (NASDAQ: ANZUU) (NASDAQ: ANZUW) ("Anzu") was approved by a vote of Envoy Medical shareholders in a special meeting held September 28, 2023. The vote follows the announcement of approval by Anzu shareholders on September 27, 2023. The business combination was originally signed in April 2023.
Envoy Medical Announces Proposed Board Slate of Experienced Medical Device and Financial Leaders
WHITE BEAR LAKE, Minnesota –September 19, 2023 – Envoy Medical® Corporation (“Envoy”), a hearing health company, today announced the proposed slate of seven directors to be voted on during the special meeting of stockholders to be held by its merger partner, Anzu Special Acquisition Corp I (“Anzu”) (NASDAQ: “ANZU,” “ANZUU” and “ANZUW”), which is expected to be held on September 27, 2023. The director nominees bring medical device industry, financial and equity capital markets expertise, including alumni of Abbott, Medtronic, Boston Scientific, Johnson & Johnson, PwC, and BCG.
Envoy Medical Appoints David R. Wells as Chief Financial Officer
WHITE BEAR LAKE, Minnesota--(Newsfile Corp. - August 24, 2023) - Envoy Medical® Corporation, a hearing health company, today announced the appointment of industry veteran David R. Wells as Chief Financial Officer. With more than 35 years of experience in corporate finance, the last 18 as CFO of publicly traded companies, Mr. Wells brings a wealth of experience to Envoy Medical, including public offerings and equity capital markets leadership.
Envoy Medical Early Feasibility Study of Breakthrough Fully Implanted Cochlear Implant Now Underway
WHITE BEAR LAKE, Minnesota – Nov. 1, 2022 – Envoy Medical® Corporation, a hearing health company focused on providing innovative technologies across the hearing loss spectrum, today announced the first patient has been enrolled and implanted in the Acclaim® Cochlear Implant early feasibility study at Mayo Clinic in Rochester, Minn. This surgery marks a key milestone for Envoy Medical on the road toward bringing the Acclaim Cochlear Implant to market. If approved by the FDA, the Acclaim would be the first-of-its-kind cochlear implant designed to be fully implanted and use the ear, rather than a microphone, to pick up sound.
Envoy Medical Welcomes Phil Segel as VP of Implant Technology & Training
Most recently Phill was VP of Technology, Research, Quality, and Regulatory at Oticon Medical where he developed all clinical and surgical training for cochlear implant and bone anchored devices, drove sponsored and investigator-initiated research activities in the US and Canada, developed the technical capability for an on-call technical support program and ensured compliance through a quality and regulatory team.
According to Phil, the reason he joined Envoy Medical was, "A fully-implantable cochlear implant not only changes treatment for patients but it brings scalability to the CI industry."
His knowledge of the cochlear implant medical device arena is superior, and we are pleased to have him join our team!
Envoy Medical Receives FDA IDE Approval to Begin Early Feasibility Study of Acclaim® Cochlear Implant
WHITE BEAR LAKE, Minnesota – June 21, 2022 – Envoy Medical® Corporation, a hearing health company focused on providing innovative technologies across the hearing loss spectrum, today announced the U.S. Food and Drug Administration (FDA) approved its Investigational Device Exemption (IDE) application to begin a clinical trial with its fully implanted Acclaim® cochlear implant. Envoy Medical’s single-center Early Feasibility Study for the Acclaim will take place at Mayo Clinic in Rochester, Minn.
Gene Berghoff Drops Lawsuit Against Envoy Medical
WHITE BEAR LAKE, Minn. – September 15, 2021 – Envoy Medical® Corporation, a hearing health company focused on providing innovative technologies across the hearing loss spectrum, today announced that a lawsuit filed against the Company by Gene Berghoff has been voluntarily dismissed with prejudice. Nothing was paid by the Company to Mr. Berghoff, and the parties will pay their own fees and costs.
“We are pleased that, after investigating his claims, Mr. Berghoff decided to drop his lawsuit," said Brent Lucas, CEO of Envoy Medical.
Independent Study Shows Esteem® Provides Significant Improvements in Hearing for Patients.
Results Published in The Journal of Laryngology & Otology Support Use of Active Middle Ear Implants in Patients with Moderate-to-Severe Sensorineural Hearing Loss Who Have Struggled with Hearing Aids
WHITE BEAR LAKE, Minn. – March 23, 2021 – Envoy Medical® Corporation, a hearing health company focused on providing innovative technologies across the hearing loss spectrum, today announced that an independent study published online in The Journal of Laryngology & Otology found that the fully implanted Esteem® osseointegrated active middle ear implant (AMEI) showed statistically significant improvements in post-operative hearing results. The study also reinforced the safety and efficacy of the Esteem® for patients with moderate-to-severe sensorineural hearing loss who have failed to benefit from traditional amplification like hearing aids.